Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
0
AbbVie (ABBV) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2220349/abbvie-abbv-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2220349
Feb 02, 2024 - The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511
Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
0
BLS Jobs Up Big: 353K, 3.7% Unemployment
https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-3-7-unemployment?cid=CS-ZC-FT-ahead_of_wall_street-2220369
Feb 02, 2024 - 353K new jobs created for January are nearly double the 180K or so analysts were looking for.
0
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
https://www.zacks.com/stock/news/2238174/why-abbvie-abbv-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2238174
Mar 08, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
0
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
https://www.zacks.com/stock/news/2245594/why-abbvie-abbv-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2245594
Mar 25, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
0
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2245659/abbvie-abbv-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2245659
Mar 25, 2024 - AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
0
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
https://www.zacks.com/stock/news/2253351/syros-syrs-up-on-fda-fast-track-tag-for-tamibarotene-in-aml?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253351
Apr 10, 2024 - The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
0
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2254098/abbvie-abbv-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2254098
Apr 11, 2024 - The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
0
Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago
https://www.zacks.com/stock/news/2197856/here-s-how-much-you-d-have-if-you-invested-1000-in-abbvie-a-decade-ago?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2197856
Dec 14, 2023 - Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
0